Kanyama, Cecilia, Molloy, Síle, Chan, Adrienne K, Lupiya, Duncan, Chawinga, Chimwemwe, Adams, Jack, Bright, Philip, Lalloo, David ORCID: https://orcid.org/0000-0001-7680-2200, Heyderman, Robert S, Lortholary, Olivier, Jaffar, Shabbar ORCID: https://orcid.org/0000-0002-9615-1588, Loyse, Angela, van Oosterhout, Joep J, Hosseinipour, Mina C and Harrison, Thomas (2020) 'One-year Mortality Outcomes From the Advancing Cryptococcal Meningitis Treatment for Africa Trial of Cryptococcal Meningitis Treatment in Malawi'. Clinical Infectious Diseases, Vol 70, Issue 3, pp. 521-524.
|
Text
ciz454.pdf - Accepted Version Available under License Creative Commons Attribution. Download (648kB) | Preview |
Abstract
In Malawi, 236 participants from the ACTA cryptococcal meningitis treatment trial were followed-up for 12 months. The trial outcomes reported at 10 weeks were sustained to 1 year. One-week amphotericinB plus flucytosine was associated with the lowest 1 year mortality (27.5% [95%CI: 16.3 to 44.1]).
Statistics
Actions (login required)
Edit Item |